John J W Park

5PUBLICATIONS
74CO-AUTHORS
Cancer diagnosisImmunology not elsewhere classifiedMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 22, 2026
Network Integrated Platform for Clinical Trials Navigation from the New South Wales Early Phase Clinical Trials Alliance.

|May 22, 2026
Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers.

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or HER2-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Jun 20, 2024
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2-Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial.

Herui Yao, Min Yan, Zhongsheng Tong

|Feb 10, 2022
Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma.

Inês Pires da Silva, Tasnia Ahmed, Jennifer L McQuade

Pageof 1

Frequent Collaborators

1 joint publications

Inês Pires da Silva

1 joint publications

Jennifer L McQuade

1 joint publications

Caroline A Nebhan

1 joint publications

Patricio Serra-Bellver